OpGen

OpGen, Inc. (NASDAQ: OPGN) operates as a precision medicine company, developing molecular diagnostic solutions to address the global threat of antimicrobial resistance (AMR). Founded in 2002 and headquartered in Rockville, Maryland, the company's business model centers on providing rapid, actionable information to clinicians for managing life-threatening infectious diseases.

A pivotal moment in the company's history was the business combination with Curetis N.V., a German molecular diagnostics firm, which closed on April 1, 2020. This merger significantly expanded OpGen's portfolio, creating a transatlantic entity by integrating Curetis' Unyvero platform and the ARES AMR database with OpGen's own diagnostic and bioinformatics technologies. The transaction aimed to create synergies in technology and commercialization, combining sales teams in the US and Europe to market a complementary product suite. Following the merger, Oliver Schacht, former CEO of Curetis, was appointed President and CEO of the combined company.

OpGen's revenue is generated from the sale of its diagnostic products, laboratory services, and through collaborations. The company serves healthcare settings, primarily hospitals, by offering tools to improve patient outcomes and support antibiotic stewardship. Its product lineup includes the Unyvero platform, a high-plex PCR system for diagnosing infectious diseases in hours, and the Acuitas AMR Gene Panel. The FDA-cleared Acuitas panel is a qualitative in vitro diagnostic test that uses real-time PCR to detect 28 genetic antimicrobial resistance markers from isolated bacterial colonies in approximately 2.5 hours. The company has also been developing the Unyvero Urinary Tract Infection (UTI) Panel. Additionally, through its subsidiary Ares Genetics, OpGen possesses the ARESdb, a comprehensive database on the genetics of antimicrobial resistance used for bioinformatics and AI-powered antibiotic response prediction.

Recent corporate filings indicate a significant strategic shift. In 2023, OpGen began a transition from precision medicine to focus on financial services and technology through a new subsidiary, CapForce International Holdings Ltd. This new venture offers listing sponsorship and consultancy services, marking a significant repositioning of the company's primary business model.

Keywords: molecular diagnostics, antimicrobial resistance, AMR, precision medicine, infectious disease diagnostics, antibiotic stewardship, Unyvero, Acuitas AMR Gene Panel, ARESdb, bioinformatics, PCR testing, microbial genetics, pathogen detection, multidrug-resistant organisms, hospital diagnostics, Curetis, Ares Genetics, clinical laboratory services, UTI panel, syndromic testing, life sciences, healthcare technology